Pasi A. Jänne

Pasi A. Jänne, MD, PhD is Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He is one of the world's foremost authorities on EGFR-targeted therapy in non-small cell lung cancer (NSCLC), with landmark contributions spanning more than two decades. Dr. Jänne was among the first to characterize acquired resistance to first-generation EGFR inhibitors through T790M mutation emergence, which directly motivated the development of third-generation inhibitors including osimertinib. He served as a principal investigator of the FLAURA trial, the pivotal phase III study demonstrating that osimertinib as first-line therapy significantly improved progression-free and overall survival compared to standard EGFR inhibitors in EGFR-mutant advanced NSCLC, establishing osimertinib as the global standard of care. Dr. Jänne has been a leading investigator for amivantamab, the EGFR-MET bispecific antibody, particularly in the setting of EGFR exon 20 insertions—a historically difficult-to-target subset—where he co-led the PAPILLON trial establishing amivantamab plus chemotherapy as a new first-line standard. He has authored more than 350 peer-reviewed publications, with an h-index exceeding 100, and is a recipient of multiple major oncology awards. His laboratory continues to define the molecular landscape of on-target and off-target resistance to third-generation EGFR inhibitors, identifying mechanisms such as MET amplification, RAS/MAPK pathway activation, and EGFR C797S mutation.